Peter Lynch fit · Growth at a reasonable price (GARP)
Is Nektar Therapeutics (NKTR) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
0/100
FNot a fit
1/6 criteria passed
Peter Lynch's Criteria, Applied to NKTR
PEG ≤ 1.0
key—
EPS CAGR ≥ 15%
key0.0%
Revenue CAGR ≥ 10%
-49.9%
Net margin > 0
-192.9%
Manageable debt (D/E < 1)
0.0x
Positive free cash flow
No
How NKTR Scores on Other Strategies
Live Financial Snapshot
Market cap
$1.3B
P/E (TTM)
-
ROIC (TTM)
-17.17%
Gross margin
99.38%
Other Peter Lynch fit reports
Frequently Asked Questions
What is NKTR's Peter Lynch fit score?
NKTR scores 0/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own NKTR?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends NKTR.
How often is this score updated?
NKTR's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends NKTR.